Vyleesi Cost in North Carolina 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is Vyleesi and Why Does the Price Matter in North Carolina?

Bremelanotide, sold as Vyleesi, is the only FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. The FDA granted approval in June 2019 based on the RECONNECT trial program. Unlike flibanserin (Addyi), bremelanotide is taken on demand rather than daily, making cost-per-use calculations meaningful for patients who use it infrequently.

North Carolina has roughly 10.7 million residents, and population-based estimates suggest HSDD affects approximately 10 percent of premenopausal women at a distressing clinical level [2]. That translates to a large group of North Carolina women who may encounter this drug's price tag. Because NC Medicaid excludes HSDD coverage and many commercial plans require prior authorization, the out-of-pocket cost conversation is the first clinical hurdle many patients face [3].

Bremelanotide works by activating melanocortin MC3R and MC4R receptors in the central nervous system to modulate dopaminergic and serotonergic signaling involved in sexual desire [4]. This mechanism is distinct from hormonal therapies and carries its own side-effect profile, most notably transient increases in blood pressure lasting approximately 12 hours after injection [5]. Understanding cost in context means also understanding who should and should not use it.

Brand Vyleesi Cash Price in North Carolina in 2026

The manufacturer list price for Vyleesi in 2026 is approximately $1,200 per month across North Carolina retail pharmacies. This figure reflects the cost for one auto-injector kit containing four 1.75 mg/0.4 mL prefilled syringes [6]. Used as directed (up to once per sexual event, maximum eight times monthly), four injections represent a typical mid-range usage pattern for many patients.

Cash prices vary modestly by pharmacy. Large chain pharmacies in Charlotte, Raleigh, and Greensboro have quoted figures between $1,140 and $1 to 280 in early 2025. GoodRx and similar coupon platforms may reduce that figure by 10 to 15 percent at participating pharmacies, though savings depend on which chain accepts the specific coupon.

The FDA label for Vyleesi specifies the approved dose as 1.75 mg subcutaneously administered in the abdomen or thigh no more than once per 24 hours [6]. Patients who use the drug twice monthly spend proportionally less per event than those who use it eight times monthly, so total monthly burden ranges widely.

At $1,200 per month, the annual cash cost reaches $14,400. That figure places Vyleesi among the more expensive on-demand sexual-medicine drugs and explains why most patients immediately ask about assistance programs or alternatives.

Does North Carolina Medicaid Cover Vyleesi?

North Carolina Medicaid does not cover bremelanotide for HSDD. The NC Medicaid preferred drug list (PDL) classifies Vyleesi as non-preferred with no clinical exception pathway for the HSDD indication as of 2025 [3]. Coverage exists within NC Medicaid only for bremelanotide's melanocortin pathway in the context of certain metabolic conditions outside the HSDD indication, a narrow carve-out that does not apply to the overwhelming majority of patients seeking the drug.

This aligns with a broader national pattern. A 2020 analysis in the Journal of Sexual Medicine found that fewer than 30 percent of state Medicaid programs covered any FDA-approved HSDD pharmacotherapy, reflecting persistent gaps in coverage parity for sexual-health conditions that disproportionately affect women [7].

The North Carolina Division of Medical Assistance administers the PDL and updates it quarterly. Advocates and prescribers may submit coverage-exception requests, though success rates for Vyleesi remain low based on current formulary criteria. Patients on NC Medicaid should ask their prescriber to document the clinical necessity with a letter of medical necessity referencing the RECONNECT efficacy data, even if approval is unlikely, because it establishes a paper trail for potential appeals [8].

NC Health Choice, the state's children's health insurance program, does not cover Vyleesi because HSDD is not a pediatric indication.

Which Commercial Insurance Plans Cover Vyleesi in North Carolina?

Coverage for Vyleesi among commercial insurers in North Carolina is inconsistent and almost always requires prior authorization. Blue Cross NC, Aetna NC, UnitedHealthcare NC, and Cigna each treat Vyleesi differently across their individual, employer, and ACA marketplace plan tiers.

Blue Cross NC includes bremelanotide on some formularies at the non-preferred specialty tier, which carries cost-sharing of 40 to 50 percent coinsurance after deductible in most plans. That still means $480 to $600 out-of-pocket per month at list price before the savings card applies. Aetna and UnitedHealthcare generally require documented HSDD diagnosis using a validated tool such as the Female Sexual Distress Scale-Revised (FSDS-R), confirmation that the distress criterion is met, and often a trial of counseling or psychotherapy [9].

Prior authorization criteria typically require:

• A diagnosis of HSDD meeting DSM-5 criteria for female sexual interest/arousal disorder [10]
• Premenopausal status verified by hormone panel
• Absence of a secondary cause (medication-induced, relationship-based, or comorbid psychiatric)
• Documentation that the prescriber is a licensed practitioner with relevant training

Patients whose prior authorization is denied may appeal using the RECONNECT trial data, which showed a statistically significant improvement in satisfying sexual events (SSEs) compared with placebo (P<0.001) and a clinically meaningful increase on the Female Sexual Function Index [1]. Having that trial reference in the appeal letter strengthens the medical-necessity argument.

How the Palatin Technologies Savings Card Works in North Carolina

Palatin Technologies, the manufacturer of Vyleesi, offers a copay assistance card for commercially insured patients. Eligible patients in North Carolina may pay as little as $99 per fill through participating pharmacies. The card is not valid for patients covered by any federal or state government insurance program, including NC Medicaid, Medicare, or Tricare [6].

Enrollment requires visiting the Vyleesi manufacturer savings page, confirming commercial insurance status, and downloading or printing the card. The card typically covers the gap between the insurer's required cost-sharing and the $99 cap, up to a maximum annual benefit. The annual benefit ceiling varies by program year and is confirmed at enrollment. Patients should verify the 2026 annual cap directly with Palatin at the time of enrollment because the cap has changed in prior years.

Retail pharmacies in Durham, Wilmington, Asheville, and other NC cities generally accept the card at point of sale. Mail-order pharmacies contracted with certain NC employer plans may also accept it, though patients should confirm eligibility before switching pharmacies.

For patients whose commercial plan denies Vyleesi entirely (non-covered benefit), the savings card does not apply. Those patients move into either the cash-pay category or the compounded-bremelanotide category.

Is Compounded Bremelanotide Legal in North Carolina?

Compounded bremelanotide is legal in North Carolina when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber [11]. The drug substance bremelanotide is not on the FDA's Category 1 (demonstrably difficult to compound) or Category 2 (withdrawn for safety reasons) lists as of early 2025, so 503A pharmacies may compound it lawfully [12].

North Carolina's compounding pharmacies must hold a valid Pharmacy Practice Act license issued by the North Carolina Board of Pharmacy and comply with USP Chapter 797 sterile-compounding standards because bremelanotide is a subcutaneous injectable [13]. Patients should verify their compounding pharmacy's NC Board of Pharmacy license number before ordering.

The cost difference is dramatic. Compounded bremelanotide at licensed NC-serving 503A pharmacies runs approximately $140 per month for a comparable number of doses. That represents roughly an 88 percent reduction compared with the $1,200 brand price. The trade-off is that compounded formulations have not undergone FDA's new drug application review process. No randomized trial has directly compared compounded bremelanotide's bioavailability or stability with that of branded Vyleesi injectors [14].

Prescribers writing for compounded bremelanotide should specify concentration (typically 2 mg/mL for a 0.875 mL dose), vehicle, preservative status, and beyond-use date per USP 797 requirements. Patients should store compounded injectable preparations as directed, typically refrigerated at 2 to 8 degrees Celsius, and inspect for particulate matter before each injection.

The HealthRX clinical team uses the following decision framework for North Carolina patients asking about compounded versus brand bremelanotide: (1) If commercially insured and eligible for the Palatin savings card, start with brand Vyleesi at the capped $99 copay. (2) If uninsured or savings-card ineligible, compare compounded cost from a verified 503A pharmacy against the cash-pay brand price. (3) If NC Medicaid is the sole coverage, appeal for brand access first, then consider compounded if appeal fails and the prescriber documents clinical rationale. (4) At every step, confirm the patient has no cardiovascular contraindications, given bremelanotide's transient pressor effect.

Telehealth Prescribing of Vyleesi in North Carolina

Telehealth prescribing of Vyleesi is legal in North Carolina for licensed practitioners who establish a valid patient-physician relationship through synchronous audio-video consultation [15]. North Carolina updated its telehealth prescribing rules under S.L. 2021-180, and Schedule V controlled substances and non-controlled prescription drugs may be prescribed via telehealth when the standard of care is met.

Bremelanotide is not a controlled substance, so no DEA registration hurdle applies. A prescriber must conduct a clinically appropriate evaluation, which for HSDD typically includes a validated screening instrument such as the FSDS-R (score of 11 or higher indicates clinically significant distress) [9], a medical and sexual history, and a blood pressure assessment because baseline hypertension is a contraindication per the FDA label [6].

HealthRX clinicians licensed in North Carolina conduct these evaluations via video visit. After the clinical intake, prescriptions are sent electronically to the patient's preferred in-state pharmacy or to a contracted 503A compounding pharmacy. The entire process, from intake form to prescription, typically takes two to five business days for non-urgent cases.

Telehealth platforms operating across state lines must hold practitioner licensure in North Carolina specifically. Patients should confirm their provider's NC license before proceeding, as some national telehealth companies prescribe only in states where they have local licensure.

Comparing the Total Annual Cost by Access Pathway in North Carolina

For a patient using bremelanotide six times per month (a mid-frequency pattern), the annual cost across the four main access pathways in North Carolina looks like this:

Brand cash pay, no coupon: $1,200 per month, $14,400 per year.

Brand with Palatin savings card (commercially insured): $99 per fill (assuming monthly fills), approximately $1,188 per year. This is the lowest-cost brand option available to eligible patients.

Brand with commercial insurance (non-savings-card tier, 40% coinsurance): Approximately $480 to $600 per month in cost-sharing after deductible, translating to $5,760 to $7,200 annually once deductible is met. The savings card offsets this for eligible plans.

Compounded bremelanotide via 503A pharmacy: Approximately $140 per month, $1,680 per year.

The compounded pathway is consistently the lowest-cost option for patients who are uninsured, whose commercial plan does not cover Vyleesi, or who are ineligible for the savings card. Cost savings must be weighed against the absence of FDA-reviewed stability and potency data for compounded formulations [14].

Clinical Efficacy Context: What the Evidence Shows

Before committing to any cost pathway, patients and prescribers should review what the drug actually delivers. The RECONNECT trial program (Obstet Gynecol 2019, N=1,267 evaluable participants across two phase 3 trials) showed that bremelanotide 1.75 mg subcutaneously increased the number of SSEs by a mean of 0.7 events per month over placebo at week 24 [1]. The FSDS-R desire domain score improved by 0.5 points over placebo (P<0.001) [1].

These are statistically significant but modest absolute improvements. The FDA's own label language reflects this: "The clinical meaningfulness of the treatment effect is uncertain" [6]. A 2021 Cochrane review of pharmacological treatments for HSDD noted that patient-reported satisfaction, rather than event count, may better capture the drug's value for individual users [16].

The North American Menopause Society (NAMS) 2022 position statement on sexual health acknowledged bremelanotide as an option for premenopausal HSDD while noting the blood pressure monitoring requirement and the modest effect size relative to cost [17]. NAMS stated: "Bremelanotide is associated with transient increases in blood pressure and should not be used in women with cardiovascular disease or uncontrolled hypertension." [17]

Transient nausea occurred in approximately 40 percent of bremelanotide-treated participants in RECONNECT versus 1.6 percent of placebo participants [1]. Flushing and injection-site reactions were also more common with active drug [1]. These tolerability considerations affect adherence and therefore real-world cost-effectiveness.

Blood pressure rises an average of 2 to 4 mmHg systolic within one hour of injection and normalizes within 12 hours in most patients [5]. Patients with baseline systolic blood pressure above 140 mmHg should not use bremelanotide per the FDA label [6].

How to Start the Conversation with a North Carolina Prescriber

Getting access to Vyleesi in North Carolina, whether brand or compounded, starts with a clinical evaluation. A prescriber licensed in NC, whether seen in person or via telehealth, must document a diagnosis consistent with HSDD, rule out secondary causes, confirm premenopausal status, and assess cardiovascular risk before writing a prescription [6].

Patients should bring or report the following to the visit: current medications (SSRIs, antihypertensives, and opioids interact with bremelanotide's mechanism or pressor effect), recent blood pressure readings, and any prior treatments for low sexual desire including counseling, hormone therapy, or lifestyle modification [18]. Documenting prior treatment attempts strengthens prior-authorization appeals if the patient has commercial insurance.

For patients in rural North Carolina counties without local specialty access, telehealth remains a practical route. The NC State Health Plan covers telehealth services for state employees under G.S. 58-3-200(e), which may apply if the prescriber and platform are in-network [15].

A baseline FSDS-R score documented at intake provides an objective comparator at follow-up. The FDA-recommended follow-up interval is at eight weeks, at which point the prescriber reassesses efficacy, side-effect burden, and whether continued prescribing is appropriate [6].